UniProtKB/SwissProt variant VAR

Variant information

Variant position:

310

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:

LP/P [Disclaimer]

The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Methionine (M) at position 310 (V310M, p.Val310Met).

Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:

Similar physico-chemical property. Both residues are medium size and hydrophobic.

The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:

1

The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page

Variant description:

In MEVA and HIDS.

Any additional useful information about the variant.

Other resources:

Links to websites of interest for the variant.

Variant rs104895319 [ dbSNP | Ensembl ]

Sequence information

Variant position:

310

The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:

396

The length of the canonical sequence.

Location on the sequence:

QYLVLEELIDMNQHHLNALG V GHASLDQLCQVTRARGLHSK

The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QYLVLEELIDMNQHHLN-ALGVGHASLDQLCQVTRARGL-HSK

Mouse                         QYLVLEELIDMNQHHLN-ALGVGHNSLDQLCQVTAAHGL-H

Rat                           QYLVLEELMDMNQHHLN-ALGVGHASLDQLCQVTAAHGL-H

Bovine                        HYLTLEELIDMNQHHLN-ALGVGHASLDQLCQVTTAHGL-H

Slime mold                    LQQTMDLMFDMNQHLLSGCYGVGHSSIDTIVSITKSLGF-H

Baker's yeast                 LYEQLLELIRINHGLLV-SIGVSHPGLELIKNLSDDLRIGS

Fission yeast                 --KKLGEFIVLNQKLLE-CLGVSHYSIDRVLQATKSIGW--

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	1 – 396	Mevalonate kinase
Mutagenesis	296 – 296	E -> Q. No change in protein stability. No effect on kinase activity.

Literature citations

Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome.
Houten S.M.; Koster J.; Romeijn G.-J.; Frenkel J.; Di Rocco M.; Caruso U.; Landrieu P.; Kelley R.I.; Kuis W.; Poll-The B.T.; Gibson K.M.; Wanders R.J.A.; Waterham H.R.;
Eur. J. Hum. Genet. 9:253-259(2001)
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS HIDS PRO-20; PRO-39; LEU-135; THR-148; THR-268 AND ILE-377; VARIANTS MEVA PRO-20; PHE-264; THR-268; MET-310 AND THR-334;

Identification and characterization of three novel missense mutations in mevalonate kinase cDNA causing mevalonic aciduria, a disorder of isoprene biosynthesis.
Houten S.M.; Romeijn G.J.; Koster J.; Gray R.G.F.; Darbyshire P.; Smit G.P.A.; de Klerk J.B.C.; Duran R.; Gibson K.M.; Wanders R.J.A.; Waterham H.R.;
Hum. Mol. Genet. 8:1523-1528(1999)
Cited for: VARIANTS MEVA MET-310 AND THR-334;

MVK mutations and associated clinical features in Italian patients affected with autoinflammatory disorders and recurrent fever.
D'Osualdo A.; Picco P.; Caroli F.; Gattorno M.; Giacchino R.; Fortini P.; Corona F.; Tommasini A.; Salvi G.; Specchia F.; Obici L.; Meini A.; Ricci A.; Seri M.; Ravazzolo R.; Martini A.; Ceccherini I.;
Eur. J. Hum. Genet. 13:314-320(2005)
Cited for: VARIANTS HIDS GLN-20; ILE-132; THR-148; ARG-171; GLU-211; GLN-215; ILE-250; ARG-265; THR-268; MET-310; VAL-376 AND ILE-377; VARIANTS ASN-52 AND MET-356;

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q03426: Variant p.Val310Met